Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.
In the wake of widespread abortion bans, US prosecutors launch hundreds of cases charging people with crimes related to their ...
After 16 years of delayed conception, mockery, and betrayal, an Anambra couple shares their emotional journey of faith, IVF, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback